<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730561</url>
  </required_header>
  <id_info>
    <org_study_id>Endo01</org_study_id>
    <nct_id>NCT00730561</nct_id>
  </id_info>
  <brief_title>Hematopoietic Stem Cell Transplantation for the Treatment of Limb Ischemia and Diabetic Neuropathy</brief_title>
  <official_title>Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Limb Ischemia and Diabetic Neuropathy in Patients With Diabetes Mellitus Type 2:A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several pathophysiological theories have been proposed for the development of diabetic
      chronic complications. In recent years, the use of stem cells (totipotential, hematopoietic
      or endothelial lineages) has been reported as an adjunctive modality of treatment for
      ischemia models in animals and humans. Nevertheless, there are no reports in the use of stem
      cells for the treatment of human sensorimotor peripheral diabetic neuropathy. We performed
      this study to evaluate the effect of autologous hematopoietic CD34+ cell transplantation on
      nerve conduction velocity in patients with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in nerve conduction velocity</measure>
    <time_frame>Three months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Limb Ischemia</condition>
  <condition>Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hematopoietic stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hematopoietic stem cell transplantation</intervention_name>
    <description>Intramuscular application of CD34+ hematopoietic stem cells (with a minimum of 2 million CD34+ cells/kg) into the gastrocnemius muscles after stimulation with subcutaneous filgrastim 600 micrograms/kilogram a day for 4 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory patients with type 2 diabetes mellitus and ischemia of one or both lower
             limbs, defined as lack of limb improvement with conventional care (medications,
             debridements) after a recent amputation or a patient graded III or IV in the
             Leriche-Fontaine functional classification.

        Exclusion Criteria:

          -  Patients older than 75 years

          -  Hypercoagulable states

          -  Cardiac ejection fraction &lt; 30%

          -  Active vasculopathy in brain, kidneys or heart

          -  Neoplastic disease

          -  Active infection

          -  Diabetic ketoacidosis or hyperosmolar hyperglycemic state

          -  Gangrene of the extremity requiring immediate surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando J Lavalle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departamento de Endocrinología del Hospital Universitario &quot;José E. González&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario &quot;José E. González&quot;</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care. 2005 Sep;28(9):2155-60.</citation>
    <PMID>16123483</PMID>
  </reference>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>August 7, 2008</last_update_submitted>
  <last_update_submitted_qc>August 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>Fernando Javier Lavalle Gonzalez</name_title>
    <organization>Departamento de Endocrinologia</organization>
  </responsible_party>
  <keyword>nerve conduction velocity</keyword>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

